Clinical Trial Results:
            Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous Marzeptacog Alfa (Activated) For On-Demand Treatment and Control of Bleeding Episodes in Subjects with Haemophilia A or Haemophilia B, with Inhibitors: The Crimson 1 Study
    
|     Summary | |
|     EudraCT number | 2020-000996-19 | 
|     Trial protocol | GB HU PL DK BG IT | 
|     Global completion date | |
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | |
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | |
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | |
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    02 Apr 2023
                             | 
|     First version publication date | 
                                    02 Apr 2023
                             | 
|     Other versions | |
|     Summary report(s) | MAA-304 CSR Synopsis | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
